Novo Nordisk A/S Common Stock (NVO)

NEW YORK, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Cardlytics, Inc. (NASDAQCDLX), Novo Nordisk A/S NYSE:NVONYSENVO)(NASDAQ:MUNASDAQMU, and ModivCare, Inc. (NASDAQ: MODVNASDAQ). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

NEW YORK, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Novo Nordisk A/S (“Novo” or the “Company”) (NYSENVO) for violations of the federal securities laws on behalf of investors who purchased or acquired Novo common stock between November 2, 2022 to December 19, 2024, inclusive (the “Class Period”).

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Novo Nordisk To Contact Him Directly To Discuss Their Options

NEW YORK, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Novo Nordisk A/S (“Novo” or the “Company”) (NYSENVO) between November 2, 2022 and December 19, 2024, inclusive.

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Novo Nordisk A/S (“Novo Nordisk” or “the Company”) (NYSENVO) and certain of its officers.

NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Novo Nordisk A/S (“Novo” or the “Company”) (NYSENVO) for violations of the federal securities laws on behalf of investors who purchased or acquired Novo common stock between November 2, 2022 to December 19, 2024, inclusive (the “Class Period”).

SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Novo Nordisk A/S (NYSENVO) is facing a class-action lawsuit from investors who allege the pharmaceutical giant misled them about the prospects of its experimental obesity drug, CagriSema.  

NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Novo Nordisk A/S (“Novo Nordisk” or the “Company”) (NYSENVO) in the United States District Court for the District of New Jersey on behalf of all persons and entities who purchased or otherwise acquired Novo Nordisk securities between November 2, 2022 to December 19, 2024, both dates inclusive (the “Class Period”). Investors have until March 25, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) --

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Novo Nordisk To Contact Him Directly To Discuss Their Options

Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Novo Nordisk A/S (NYSENVO) securities between November 2, 2022 and December 19, 2024, both dates inclusive (the “Class Period”), have until March 25, 2025 to seek appointment as lead plaintiff of the Novo Nordisk class action lawsuit. Captioned Moon v. Novo Nordisk A/S, No. 25-cv-00713 (D.N.J.), the Novo Nordisk class action lawsuit charges Novo Nordisk and certain of Novo Nordisk’s top executives with violations of the Securities Exchange Act of 1934.

SAN DIEGO, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Novo Nordisk A/S (NYSENVO) securities between November 2, 2022 and December 19, 2024. Novo is a healthcare company, focused on the research, development, manufacturing, and distribution of pharmaceutical productions globally.

Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities of Novo Nordisk A/S (NYSENVO) between November 2, 2022 and December 19, 2024. Novo describes itself as a “healthcare company, focused on the research, development, manufacturing, and distribution of pharmaceutical productions globally.”

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Novo Nordisk A/S (“Novo” or “the Company”) (NYSENVO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Novo Nordisk A/S (NYSENVO) securities between November 2, 2022 and December 19, 2024, inclusive (the “Class Period”), have until March 25, 2025 to seek appointment as lead plaintiff of the Novo Nordisk class action lawsuit. Captioned Moon v. Novo Nordisk A/S, No. 25-cv-00713 (D.N.J.), the Novo Nordisk class action lawsuit charges Novo Nordisk and certain of Novo Nordisk’s top executives with violations of the Securities Exchange Act of 1934.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Novo Nordisk To Contact Him Directly To Discuss Their Options

Energy drinks face negative publicity and competition, leading to sell-offs in Monster and Celsius. Increasing foot traffic may offer hope for a recovery.

One Wall Street analysts recently singled out a drug from pharma company Roche as a threat to Eli Lilly's oral GLP-1 candidate.

Eli Lilly is the most valuable pharmaceutical company in the world. I believe the company has what it takes to stay there.

Skye Bioscience has incredible potential upside, according to Wall Street analysts. It is striving to make a new weight loss drug, that could work with GLP-1s.

Check out these three micro-cap companies that have a big opportunity to succeed, but also significant a risk of failure.

Check out these three stocks each up over 60% in the past twelve months. Their strong paths for growth can help keep their momentum stories going.

NetworkNewsWire Editorial Coverage : Alzheimer’s disease (“AD”) has become a focal point in the pharmaceutical industry as recent drugs such as Leqembi and Kisunla have received U.S. Food and Drug Administration (“FDA”) approval. However, while these treatments may slow cognitive decline in AD patients, they do not actually improve cognition, a critical target for the millions suffering from the progressive disease. In addition, GLP-1 (glucagon-like peptide-1) drugs, which were originally developed to manage type 2 diabetes and since have seen significant effectiveness in treating obesity, have also shown potential in the treatment of Alzheimer’s. However, there is no molecule or a combination of molecules that enhance cognitive functions. Thanks to innovative approaches by companies such as Annovis Bio Inc. (NYSEANVS) ( profile ), there is reason to be optimistic about potential future breakthroughs in the AD space. Annovis has completed early research with compelling results utilizing its lead drug, buntanetap, in combination with popular drugs approved for other indications. Broadly speaking, there is ample reason to be bullish on new treatments for a variety of significant diseases, including AD and obesity, as companies such as Eli Lilly NYSE: LLYNYSELLY)(NYSE: PFENYSEPFE , Novo Nordisk (NYSE: NVONYSE) and AbbVie Inc. (NASDAQ: ABBVABBV) are making investments and progress on historically…

EQNX::TICKER_START (NYSEANVS),NYSE:LLYNYSELLY)(NYSE:PFENYSEPFE,(NYSE:NVONYSE),(NASDAQ:ABBVABBV) EQNX::TICKER_END

Novo Nordisk has received both good and bad news recently when it comes to weight loss and diabetes drugs. So, where does the firm stand now?